Last reviewed · How we verify
NCT05420259
Combined Exercise and Nutritional Intervention in GI Cancer Patients
NA trial testing Combined Exercise and Dietary Intervention (CEDI) in Pancreatic Cancer in 68 participants. Status unknown.
28 June 2024
Quick facts
| Lead sponsor | Hospital Beatriz Ângelo |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 68 |
| Start date | 21 March 2022 |
| Primary completion | 28 June 2024 |
| Estimated completion | 28 June 2024 |
| Sites | 2 locations across Portugal |
Drugs / interventions tested
- Combined Exercise and Dietary Intervention (CEDI)
- Standard Care — full drug profile →
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Gastric Cancer — all drugs for Gastric Cancer →
- Diet — all drugs for Diet →
- Exercise — all drugs for Exercise →
Sponsor
Hospital Beatriz Ângelo
Who can join
Adults 40 to 80, any sex, with Pancreatic Cancer or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although some studies have focused on the role of exercise on inflammation and cytokine expression in cancer patients undergoing treatment and survivors, to our knowledge none have investigated the effect of exercise during neoadjuvant treatment as a complementary therapy to 1) modulate inflammation which may have a positive influence on chemotherapy response and 2) preserve or improve skeletal muscle, thus preventing cancer cachexia. Furthermore, we believe that the neoadjuvant treatment period could be a window of opportunity to optimize patient's nutritional status before surgery, which until now has been under used. Bearing in mind that nutritional interventions may also influence IL-6, our hypothesis is that a Combined Exercise and Dietary Intervention (CEDI) may induce positive alterations in cytokine profile and increase NK cell infiltration of the tumor in gastric and pancreatic cancer patients submitted to neo-adjuvant therapy.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review.
Guo Y, Han S, Yu W, Xu Y, et al · · 2025 · cited 3× · PMID 39925900 · DOI 10.21037/hbsn-24-282 -
Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier.
Brugiapaglia S, Spagnolo F, Curcio C. · · 2025 · cited 1× · PMID 40427617 · DOI 10.3390/biom15050725 -
Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.
Okamura M, Shirado K, Shirai N, Yagi T, et al · · 2026 · PMID 41884877 · DOI 10.2490/prm.20260012
Verify or expand the search:
- PubMed search for NCT05420259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Combined Exercise and Dietary Intervention (CEDI)
Trials testing the same drug.
- NCT05237921 — Adherence to Exercise and Dietary Intervention in Cancer Patients · NA · completed
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Hospital Beatriz Ângelo trials
Trials by the same sponsor.
- NCT03860324 — Erector Spinae vs Fascia Iliaca Block in Hip Arthroplasty · NA · withdrawn
- NCT03726281 — Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors · Phase 2 · withdrawn
- NCT05237921 — Adherence to Exercise and Dietary Intervention in Cancer Patients · NA · completed
- NCT03856957 — Serrated Lesions Detection With Endocuff-assisted Colonoscopy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05420259 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Beatriz Ângelo
- Last refreshed: 19 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05420259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing